ArriVent BioPharma reported cash from operations of -$40.71M and free cash flow of -$40.71M for the quarter ended Sep 2026, down 13.7% year over year. This cash flow statement covers 16 quarters of results from Dec 2022 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow StatementCash Flow | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Net Income | -12.17M | -21.57M | -14.40M | -21.19M | -17.42M | -21.87M | -20.56M | -20.63M | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M | -49.89M | -40.31M | |
| Depreciation, Depletion & Amortization | ||||||||||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | -0.56M | -0.52M | -0.65M | |||||||||||||
| Share-based CompensationStock Comp. | 0.17M | 193.00M | 216.00M | 0.32M | 0.63M | 0.77M | 0.87M | 0.95M | 2.27M | 3.31M | 3.72M | 3.22M | 5.49M | 6.67M | 6.88M | |
| Change in Working Capital | ||||||||||||||||
| Change in Account PayablesChange Payables | -0.38M | 3.69M | -2.23M | 0.30M | -0.37M | -0.35M | 0.83M | -0.87M | 0.58M | -0.30M | 1.87M | -0.01M | 2.81M | -6.51M | 0.40M | |
| Change in Accrued ExpensesChange Accrued Exp. | -2.04M | 3.18M | -1.22M | 1.64M | -0.96M | 2.14M | 2.23M | 2.97M | -4.88M | 7.03M | 0.09M | 4.43M | -3.83M | 9.14M | -4.57M | |
| Change in Other Operating AssetsOther Assets Change | 2.46M | -5.89M | -2.19M | -4.01M | 0.51M | -0.23M | -0.30M | -1.43M | 1.59M | 4.76M | 6.49M | -0.28M | 2.52M | -1.60M | 2.43M | |
| Change in Other Operating LiabilitiesOther Liabilities Change | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M | -0.01M | -0.01M | -0.01M | 0.05M | -0.07M | -0.03M | |||||
| Other Working Capital ChangesOther WC Changes | -2.46M | 5.89M | 2.19M | 4.01M | -0.50M | 0.22M | 0.29M | 1.42M | -1.60M | -4.76M | -6.50M | 0.27M | -2.48M | 1.53M | -2.46M | |
| Cash from OperationsCash from Ops. | -16.88M | -8.61M | -15.44M | -14.91M | -18.63M | -19.09M | -16.35M | -16.15M | -68.01M | -26.12M | -35.80M | -30.66M | -41.89M | -39.58M | -40.71M | |
| Investing Activities | ||||||||||||||||
| Purchase of InvestmentsInvestments Purchased | 9.82M | 21.57M | 90.37M | 151.18M | 64.38M | 13.99M | 126.22M | |||||||||
| Sale and Maturity of InvestmentsInvestments Sold | 46.64M | 35.48M | 39.61M | 79.98M | 67.97M | 60.07M | 65.57M | |||||||||
| Cash from Investing ActivitiesCash from Investing | 36.82M | 13.91M | -50.76M | -71.20M | 3.58M | 46.07M | -60.65M | |||||||||
| Financing Activities | ||||||||||||||||
| Change in Capital Stock | ||||||||||||||||
| Common Stock IssuedStock Issued | 0.03M | 0.00M | 0.04M | 0.29M | 0.00M | 0.04M | 186.48M | 0.06M | 6.81M | 75.42M | 86.17M | 34.74M | 54.87M | 86.09M | 60.26M | |
| Net Shares Issued and RepurchasedNet Shares Issued | 0.03M | 0.00M | 0.04M | 0.29M | 0.00M | 0.04M | 186.48M | 0.06M | 6.81M | 75.42M | 86.17M | 34.74M | 54.87M | 86.09M | 60.26M | |
| Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued | 44.94M | -0.02M | ||||||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 44.97M | -0.02M | 0.04M | 0.29M | 0.00M | 0.04M | 186.48M | 0.06M | 6.81M | 75.42M | 86.17M | 34.74M | 54.87M | 86.09M | 60.26M | |
| Other financing activities (as filed) | -1.34M | -0.05M | -0.30M | 0.30M | -0.02M | |||||||||||
| Cash from Financing ActivitiesCash from Financing | 44.97M | -0.02M | -1.03M | -1.06M | 185.63M | 0.36M | 0.53M | 0.06M | 6.76M | 75.11M | 86.47M | 34.73M | 54.87M | 86.09M | 60.26M | |
| Additional items | ||||||||||||||||
| Change in Cash | 28.09M | -33.63M | -16.48M | 9.03M | 167.00M | -18.72M | -15.81M | -208.56M | -24.43M | 62.90M | -0.09M | -67.13M | 16.56M | 92.58M | -41.10M | |
| Ending Cash Balance | 163.37M | 191.46M | 157.83M | 141.36M | 150.39M | 317.39M | 298.67M | 282.86M | 74.29M | 49.87M | 112.77M | 112.67M | 45.54M | 62.10M | 154.68M | 113.58M |
| Free Cash FlowFCF | -16.88M | -8.61M | -15.44M | -14.91M | -18.63M | -19.09M | -16.35M | -16.15M | -68.01M | -26.12M | -35.80M | -30.66M | -41.89M | -39.58M | -40.71M | |
| Net Cash FlowNCF | 28.09M | -8.63M | -16.48M | -15.97M | 167.00M | -18.72M | -15.81M | -16.10M | -24.43M | 62.90M | -0.09M | -67.13M | 16.56M | 92.58M | -41.10M |
Pull ArriVent BioPharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=AVBP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "AVBP", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=AVBP&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();